These findings provide a strong rationale for blocking the PD-1/PD-L1 axis by immuno-oncology (23), especially in the case of aggressive tumors with high recurrence and relapse rates whose treatment is challenging, such as HNSCC (1). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.